News & Recent Work

Recent Work

Azevedo Sette assisted Méliuz’s shareholders a secondary offering

Méluiz sold over 58 million shares on Brazil’s B3 stock exchange for 10 reais (US$1.85) each. That was on the lowest rung of a target range between 10 reais (US$1.85) and 12.50 reais (US$2.31). Méluiz issued 22,360,000 shares as primary stock, with the proceeds returned to...

Azevedo Sette advised Grupo Toro and shareholders in the sale to Santander subsidiary Pi

Azevedo Sette Advogados has advised Grupo Toro and its private shareholders in the sale of 60% of their equity interest to Santander subsidiary Pi....

Azevedo Sette assisted Grupo Promed in the sale of the company to Hapvida

Madrona Advogados has helped Brazilian health insurance company Hapvida buy local healthcare group Promed in a deal worth 1.5 billion reais (US$279 million). Promed turned to Azevedo Sette Advogados. The deal was signed on 8...

Azevedo Sette was legal advisor to Vita Participações in the acquisition of Instituto de Hematologia de Goiânia

Azevedo Sette was legal advisor to Vita Participações S/A in the acquisition of 64,3% of the capital stock of Instituto de Hematologia de Goiânia...

Azevedo Sette Advogados assisted SDFLCs quotaholders of to sell of the company to Frutarom

Azevedo Sette Advogados assisted the quotaholders of SDFLC Brasil Indústria e Comércio Ltda., to sell a 20% participation in the company to Frutarom do Brasil Indústria e Comércio Ltda., a company controlled by the Israeli based Frutarom...

Leprino Foods completa compra de todas las acciones de Lactojara

...

Azevedo Sette advised Vita Participações in the acquisition of Hemolad

Azevedo Sette was legal advisor to Vita Participações S/A in the acquisition of 100% of the capital stock of Hemolad Serviços de Hemoterapia e Hematologia Ltda. Amount involved is confidential. Closed in February...

Azevedo Sette was legal advisor to Vita Participações in the acquisition of Laboratório Integrado

Azevedo Sette was legal advisor to Vita Participações S/A in the acquisition of 90% of the capital stock of Laboratório Integrado de Análises Clinicas do Rio de Janeiro. Amount involved is confidential. Closed in October...
prev next